Search and Browse
Download
Enter Data
| Reaction Details | |||
|---|---|---|---|
 | Report a problem with these data | ||
| Target | Voltage-dependent L-type calcium channel subunit alpha-1C | ||
| Ligand | BDBM50001885 | ||
| Substrate/Competitor | n/a | ||
| Meas. Tech. | ChEMBL_1479154 (CHEMBL3436130) | ||
| IC50 | 125000±n/a nM | ||
| Citation |  Wisniowska, B; Mendyk, A; Fijorek, K; Glinka, A; Polak, S Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment. J Appl Toxicol32:858-66 (2012) [PubMed] Article | ||
| More Info.: | Get all data from this article, Assay Method | ||
| Voltage-dependent L-type calcium channel subunit alpha-1C | |||
| Name: | Voltage-dependent L-type calcium channel subunit alpha-1C | ||
| Synonyms: | CAC1C_HUMAN | CACH2 | CACN2 | CACNA1C | CACNL1A1 | CCHL1A1 | Calcium channel (Type L) | Calcium channel, L type, alpha-1 polypeptide, isoform 1, cardiac muscle | L-type calcium channel alpha-1c/beta-2/alpha2delta-1 | Voltage-dependent L-type calcium channel subunit alpha-1C | Voltage-gated L-type calcium channel | Voltage-gated L-type calcium channel alpha-1C subunit | Voltage-gated calcium channel | Voltage-gated calcium channel subunit alpha Cav1.2 | ||
| Type: | Enzyme Catalytic Domain | ||
| Mol. Mass.: | 248979.79 | ||
| Organism: | Homo sapiens (Human) | ||
| Description: | Calcium channel (Type L) 0 HUMAN::Q13936 | ||
| Residue: | 2221 | ||
| Sequence: |
| ||
| BDBM50001885 | |||
| n/a | |||
| Name | BDBM50001885 | ||
| Synonyms: | (risperidone)3-{2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-2-methyl-6,7,8,9-tetrahydro-pyrido[1,2-a]pyrimidin-4-one | 1-(2-Allyl-phenoxy)-3-isopropylamino-propan-2-ol | 2-(2-(4-(benzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-7,8,9,9a-tetrahydro-1H-pyrido[1,2-a]pyrimidin-4(6H)-one | 2-{2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-6,7,8,8a-tetrahydro-5H-naphthalen-1-one | 3-(2-(4-(6-fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one | 3-{2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-2-methyl-6,7,8,9-tetrahydro-pyrido[1,2-a]pyrimidin-4-one | 3-{2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-2-methyl-6,7,8,9-tetrahydro-pyrido[1,2-a]pyrimidin-4-one (Resperidone) | 3-{2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-2-methyl-6,7,8,9-tetrahydro-pyrido[1,2-a]pyrimidin-4-one (risperidone) | 3-{2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-2-methyl-6,7,8,9-tetrahydro-pyrido[1,2-a]pyrimidin-4-one(risperidone) | 5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-6-methyl-1,3-dihydro-indol-2-one(Norastemizole) | CHEMBL85 | R 64 766 | RISPERDAL | RISPERIDONE | US10167256, Risperidone | US10174011, risperidone | US10259786, Risperidone | US10501452, Compound risperidone | US8802672, Risperidone | WO2023288027, Cmpd Risperidone | ||
| Type | Small organic molecule | ||
| Emp. Form. | C23H27FN4O2 | ||
| Mol. Mass. | 410.4845 | ||
| SMILES | Cc1nc2CCCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12 | ||
| Structure | 
| ||